SCHEMBL1072292

SCHEMBL1072292

COC(=O)c1c(N(C)C)ccc([N+](=O)[O-])c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.44
MAPT P10636 10/20 0.41
ALDH1A1 P00352 8/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
KDM4E B2RXH2 4/20 0.41
MAPK1 P28482 3/20 0.41
LMNA P02545 3/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
ABCC4 O15439 1/20 0.41
PLIN1 O60240 1/20 0.41
CACNA1F O60840 1/20 0.41
GMNN O75496 1/20 0.41
KCNK2 O95069 1/20 0.41
ABCB11 O95342 1/20 0.41
GSR P00390 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1071311 0.79 KMT2A (0.43) MAPTALDH1A1SMN1; SMN2KDM4EMAPK1
SCHEMBL4689028 0.79 TDP1 (0.44) MAPTALDH1A1SMN1; SMN2KDM4EMAPK1
SCHEMBL1069184 0.79 TDP1 (0.53) MAPTALDH1A1SMN1; SMN2KDM4EMAPK1
SCHEMBL1072166 0.78 HCAR3 (0.46) HCAR3MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL4694230 0.75 ALDH1A1 (0.43) MAPTALDH1A1SMN1; SMN2KDM4EMAPK1
SCHEMBL4694223 0.75 ALDH1A1 (0.43) MAPTALDH1A1SMN1; SMN2KDM4EMAPK1
SCHEMBL1110902 0.74 HCAR3 (0.70) HCAR3MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL9847247 0.73 MAPT (0.46) HCAR3MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL5310060 0.72 KMT2A (0.47) MAPTALDH1A1SMN1; SMN2KDM4EMAPK1
SCHEMBL27362998 0.71 ALDH1A1 (0.48) MAPTALDH1A1SMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039895-A1 PROLYL HYDROXYLASE INHIBITORS Glaxo Smith Kline LLC., a corporation 2011-02-17 US disclosed
EP-2273879-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2011-01-19 EP disclosed
WO-2009134850-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039895-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 HCAR3 967/4885MAPT 4507/4885ALDH1A1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.